You are here: Home » International » News » Others
Business Standard

AstraZeneca's volunteer who died didn't get Covid-19 vaccine: Report

Brazil's health authority Anvisa said it had been informed on Monday of the study volunteer's death and had received a partial report from an international committee assessing the trial's safety

Brazil | AstraZeneca | Coronavirus Vaccine


Photo: Reuters
Photo: Reuters

A participant who died during a trial of Plc’s Covid-19 vaccine in hadn’t received the company’s shot, according to a person familiar with the matter.

The person asked not to be identified because the information isn’t public.

Brazil’s health authority Anvisa said it had been informed on Monday of the study volunteer’s death and had received a partial report from an committee assessing the trial’s safety. That committee suggested the trial should continue, Anvisa said in a statement.

AstraZeneca, which is developing the vaccine with the University of Oxford, said it can’t comment on individual cases because of confidentiality and clinical trial rules. Oxford has no concerns about the safety of the vaccine trial after an independent and careful review, and Brazil’s regulators have recommended that it continue, university communications head Stephen Rouse said in statement.

AstraZeneca’s American depositary receipts fell as much as 3.3% in New York on Wednesday afternoon after word of the person’s death, but trimmed most of those losses in recent trading.

US Trial Pause

A clinical trial of the vaccine in the US has been on hold for more than a month. Studies were halted globally in September when a U.K. participant became ill, but have resumed in the U.K., Brazil, Japan, South Africa and India in recent weeks. While temporary pauses in vaccine studies are common, and Oxford have faced pressure to disclose more information about the U.K. episode.

Japan’s Ministry of Health has requested details from on the death in the trial, Chief Cabinet Secretary Katsunobu Kato said Thursday. The ministry continues to work with companies to ensure proper vaccine trials are taking place in Japan, he said.

Interruption of the US trial raised concerns about the prospects of one of the world’s fastest-moving shots and highlighted the hurdles researchers face when developing a vaccine. Another vaccine maker, Johnson & Johnson, said earlier this month that it would pause its trial to investigate an illness in a study participant.

Both the AstraZeneca and J&J vaccines are based on adenoviruses, cold germs that researchers have used in experimental therapies for decades, and the two paused trials have raised questions about the approach.

AstraZeneca told analysts in early October that it expected the US study could resume this year and that global approval would be determined by results in tests outside the US

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, October 23 2020. 01:36 IST